Stifel raises Revvity stock price target to $177 on AI demand

Stifel raised its Revvity price target to $177 from $110 but maintained a Hold rating, citing above-consensus results and demand benefits related to AI; shares were quoted at $159.07, up 89% over six months. Revvity’s third-quarter 2026 adjusted EPS of $1.37 and revenue of $729 million exceeded estimates of $1.30 and $694.72 million, respectively, while 7% organic growth and margin improvement supported higher full-year guidance. Stifel cautioned that 29 times forward earnings may be elevated if consensus organic growth reaches only about 5% in 2027.

Analysis

The key question is whether AI-related demand is incremental and repeatable—or mainly a narrative attached to a cyclical recovery in research spending. If high-content screening and software improve workflow productivity, Revvity could gain recurring software attachment and become less exposed to instrument replacement cycles. But until management quantifies AI-linked bookings, software growth, and conversion into revenue, this is an option value, not a separately underwritable earnings stream. The reported benefit from prior-quarter push-offs also makes the pace of underlying acceleration harder to read.

After a sharp rerating, the bar has moved from beating estimates to demonstrating durable growth sufficient to support the multiple. That leaves near-term earnings momentum intact but worsens downside asymmetry if investor-day commentary fails to lift the medium-term growth profile. Danaher and Thermo Fisher could benefit from broader recovery in lab spending, but Revvity-specific AI traction would not automatically transfer to them.

Over 1–3 months, investor-day detail and evidence in orders, software growth, and organic growth are the main catalysts. Over 6–18 months, the thesis depends on sustained customer budgets and software monetization; a renewed funding or end-market slowdown could expose the premium valuation. The contrarian risk is that a strong quarter and AI narrative are being discounted too quickly—but the push-off caveat and absent quantified AI contribution argue against chasing. Falsification: subsequent organic growth or guidance falls below the current trajectory, or management cannot substantiate software/AI conversion.

Key Decisions for Investors

• Do not chase RVTY after the rally; hold existing exposure only if the position is sized for a valuation-led pullback. The upside case now requires evidence beyond another quarterly beat.
• Use investor day as a gating event before adding: look for quantified software growth, AI-related bookings or customer adoption, and an explicit bridge from these drivers to medium-term organic growth. If those disclosures are absent, treat AI as narrative rather than incremental earnings power.
• Alert for a downside setup if guidance or organic growth decelerates while valuation remains elevated; reassess or reduce exposure rather than assuming the recent acceleration is structural. A sustained step-up in software growth and guidance would invalidate that cautious stance.